Also first phase I clinical trial of gene electrotransfer in patients with metastatic melanoma was reported. Electroporation mediated delivery of a plasmid coding gene for interleukin-12 (pIL-12) was performed and safety, tolerability and therapeutic effect were monitored. Study concluded, that gene electrotransfer with pIL-12 is safe and well tolerated. In addition partial or complete response was observed also in distant non treated metastases, suggesting the systemic treatment effect. Based on these results they are already planning to move to Phase II clinical study. There are currently several ongoing clinical studies of gene electrotransfer, where safety, tolerability and effectiveness of immunization with DNA vaccine, which is administered by the electric pulses is monitored.